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The Chelyabinsk region is a classic example of the
technologically-saturated region. The index of pollution of
atmospheric air is estimated as high. The Chelyabinsk region is
among the areas of increased cancer risk. The incidence of head
and neck cancer is steadily increasing, accounting for 20–25% of
all cancer cases in Russia. Oropharyngeal cancer makes up 5.1%
of all cancers.
Materials and methods: The object of the study was the
population of the Chelyabinsk region. The analysis was
conducted according to the materials of the annual reports of
the statistics department of the Chelyabinsk district oncology
dispensary.
Results: Out of the total cancer cases for the population of Che-
lyabinsk region in 2014, oro-pharyngeal cancer comprised 2.06%,
including cancers of the lip (0.35%), tongue (0.47%), major salivary
glands (0.22%), other unspecified parts of the mouth (0.52%),
oropharynx (0.33%), nasopharynx (0.1%) and hypopharynx
(0.07%). From 2008 to 2014, the incidence of oral and pharyngeal
cancer among adult population of Chelyabinsk city and
Chelyabinsk region showed an 8.8% increase. In the period from
2011 to 2014, the incidence of oral and pharyngeal cancer tended
to increase, the overall rise being 71.8%. It should be noted that
the oral and pharyngeal cancer incidence was 3 times higher in
males than in females in 2013 and 2 times higher in 2014.
One of the main indicators that determine the prognosis for the
development of cancer, is the extent of tumor at time of
diagnosis.
Out of the total cancer cases for the population of Chelyabinsk
region in 2014, cancer of the oral cavity comprised 1.33%, pharyn-
geal cancer 0.6%, lip cancer 0.13%, ranking the 17th, 19th and 24th
place respectively among the causes of death from all cancers.
Analyzing the dynamics of mortality from cancer of the oral cav-
ity and pharynx during the study period, it was revealed that the
mortality rate increased by 0.7%.
Conclusion: Head and neck tumors are a rare group of clini-
cally and biologically diverse neoplastic diseases. Among the res-
idents of the Chelyabinsk region, men are 2–3 times more
susceptible to cancer of the oral cavity and pharynx than women.
High mortality rate is due to late referral of patients to specialized
clinics; most head and neck cancer patients are diagnosed at
advanced stages.
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Background: To evaluate the clinical symptoms in pancreatic
cancer patients (PCa) and compare some biochemical blood
serum parameters in patients with different pathology of the
pancreas (PCa, acute (OP) and chronic pancreatitis (CP)).
Materials and methods: During a one-time clinical research on
the type of ‘‘series of cases” 130 patients were examined
(42 patients with OP, 81 – CP and 7 patients with PCa). The diagno-
sis of PCa, OP, CP was verified by clinical and instrumental
methods. Glucose, cholesterol, triglyceride and bilirubin serum
levels were determined by ELISA.
Results: The mean age of patients with PCa was 63.6
± 4.9 years, morbidity duration of PCa – 3.5 ± 1.1 months. Among
patients with PCa, 83.3% of people – smoked, 16.7% – smoked
every day. Half of the respondents PCa patients noted that over
the last year they did not drink alcohol; 16.7% of people – drank
alcohol several times a year, and 33.3% of patients consumed
alcohol 1–2 times a month. BMI of PCa patients was equal to
26.3 ± 3.5 kg/m2, in OP patients – 23.8 ± 1.0 kg/m2, in CP patients
– 26.3 ± 0.6 kg/m2, p > 0.05. In this case, 85.7% of PCa patients
noted a significant decrease in body weight (11.7 ± 6.0 kg) for
3–4 months after the onset of symptoms. There was no pain in
42.8% of PCa patients, and frequent pain noted only in 28.6% of
persons. Among CP patients, frequent and persistent pain noted
in 65.5% of patients and among OP patients in 48.6% of cases.
All PCa patients experienced pain in the right upper quadrant.
Pain was of low intensity in 75% of cases and moderate in 25%
of cases. Elimination of pain was observed in half of the PCa
patients, and 1/4 of patients continued to experience pain. Epi-
sodes of nausea and vomiting noted in 25% of PCa patients.
Bloated feeling in the stomach and overflow were noted in
42.8% of the all surveyed PCa persons. The level of glucose in
PCa patients exceeded the normal limits and was significantly
higher compared to that in OP and CP patients (8.5 ± 1.4 mmol/L,
5.4 ± 0.3 and 5.1 ± 0.1 mmol/L, respectively, p < 0.05). Hyperbiliru-
binemia was detected in PCa patients – 89.9 ± 27.5 lmol/L; in OP
and CP patients bilirubin levels were 32.2 ± 11.0 and 13.4
± 1.8 lmol/L, respectively, which were significantly lower than
those in patients with PCa, p < 0.05. Triglyceride levels did not
differ in patients with different pancreas diseases (PCa – 1.7 ± 0.3,
CP – 1.86 ± 0.1 and OP –1.88 ± 0.11 mmol/L, p > 0.05). However,
the total cholesterol in CP patients was significantly higher
than that in PCa and OP patients (5.8 ± 0.1, 5.0 ± 0.6 and
4.1 ± 0.2 mmol/L, p < 0.05). In PCa patients, the elevated levels of
some markers of cholestasis and hepatocyte injury were
also found: ALP – 185.0 ± 12.7 IU/L, ALT – 108.4 ± 33.5 IU/L,
AST – 85.3 ± 31.5 IU/L, amylase – 44.9 ± 14.9 IU/L, fibrinogen –
2696.6 ± 398.6 g/L.
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